Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BAY 1834845

Drug Profile

BAY 1834845

Alternative Names: BAY 1834845; IRAK-4 inhibitor - Bayer

Latest Information Update: 28 Aug 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Skin disorder therapies
  • Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pelvic inflammatory disorders; Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 20 Jul 2018 Bayer completes a phase I trial in Pelvic inflammatory disorders (In volunteers) in Netherlands (IV) (PO) (NCT03244462)
  • 16 Apr 2018 Phase-I clinical trials in Psoriasis in Germany (PO) (NCT03493269)
  • 16 Apr 2018 Phase-I clinical trials in Rheumatoid arthritis in Germany (PO) (NCT03493269)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top